Wave Life Sciences reports promising phase 1 results for obesity therapy WVE-007, showing fat loss and increased lean mass.

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

Wave Life Sciences Ltd. ( WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity December 8, 2025 8:30 AM EST ...

Interim data from Wave Life Sciences' INLIGHT trial showed promising results for WVE-007, an investigational treatment for obesity.

As the World Health Organization conditionally recommends the use of GLP-1 medications to treat obesity, a Halifax-based ...

Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.

The clinical-stage biotechnology company announced that a single 240 mg dose of WVE-007 demonstrated improved body composition after three months, including a 9.4% reduction in visceral fat, a 4.5% ...

Wave Life Sciences Ltd. (NASDAQ:WVE) soared 40% on Monday after releasing interim findings from its Phase 1 INLIGHT study ...

Single-dose results showed clear shifts in visceral fat, total fat, and lean mass at three months. ・Activin E levels dropped ...

Results showed that people with obesity had blood biomarkers for Alzheimer’s that rose more rapidly, including: Tau proteins, ...